Waldencast Acquisition Corp. (NASDAQ:WALD) announced this morning that it has added $225 million in debt to its combination with beauty brands OBAGI and Milk.
This new money comes in the form of a four-year secured first-lien made up of a $175 million term loan and a $50 million revolving loan facility with $7.5 million available to be drawn as letters of credit. JP Morgan Chase (NYSE:JPM), Santander (NYSE:SAN) and Wells Fargo (NYSE:WFC) served as joint bookrunners and lead arrangers for the facility with JPM serving as administrative agent and Credit Suisse (NYSE:CS) as documentation agent.
The combined company would now receive $1.02 billion in total proceeds as this debt joins $333 million in forward purchase agreements (FPAs), a $113 million PIPE and Waldencast’s $345 million trust before redemptions. The PIPE and FPAs already covered the $440 million collective minimum cash conditions for the two companies, but the debt further secures all of the uses that the targets had in mind.
At announcement, the parties envisaged paying out $520 million in cash consideration to selling shareholders of the two companies and this new facility is aimed at paying down and replacing all of the companies’ existing credit facilities as well. Even in a 100% redemptions scenario, the combined company is now expected to have about $94 million in new capital to work with after expenses and consideration to sellers.
Waldencast initially announced the $1.2 billion combination with OBAGI and Milk Makeup on November 15. OBAGI provides medical-grade skincare products and Milk Makeup provides clean 100% vegan cosmetics via retail stores and its native ecommerce site.
The parties have not yet set a date for a completion vote on the deal, but on June 13, Waldencast announced an agreement with Obagi and Cedarwalk pertaining to the value of and cost associated with inventory on hand. As of five business days before the special shareholder meeting, the cost of inventory will be deducted from the cash portion of the consideration payable under the Obagi merger agreement to Cedarwalk.
Obagi Hong Kong will pay Obagi and certain affiliates a royalty of 2.75% of gross sales on the specific inventory identified in the agreement that is sold during the 90 days following the completion of the transaction.


Terms Tracker for the Week Ending July 3, 2025 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. We’re heading into the July 4th holiday, so we’ll keep this week’s column short and to the point. But before you head to the beach,...
Crown PropTech (OTC:CPTKW) has entered into a definitive agreement to combine with rare earth mining firm Mkango Resources (TSX-V:MKA) at a pre-money equity value of $400 million. London-based Mkango is working to commercialize a chain of rare earth mining and refining facilities in Africa and Europe. The combined company is expected to trade on the...
At the SPAC of Dawn One of the biggest sources of uncertainty in the SPAC market in recent years has been regulatory changes, but new shifts could be in its favor. SEC Chairman Paul Atkins told CNBC yesterday that the commission would review the rules for SPACs after “rather controversial” changes to the rules passed...
McKinley Acquisition Corporation (NASDAQ:MKLYU) has filed for a $150 million SPAC to hunt for an innovative target company with an experienced financial team that has dabbled in SPACs before. The new SPAC is offering investors one right to a 1/10 share in each unit with no overfunding of the trust, but it could provide a...
At the SPAC of Dawn The rain of SPACs has continued with four expected to make their debuts during today’s trading sessions after pricing their IPOs overnight. The largest of these, EQV Ventures II (NASDAQ:EVACU), even managed an upsize, making it the largest SPAC IPO since Ares II (NYSE:AACT) pulled together $450 million in 2023....